Vertex Pharmaceuticals Inc. (VRTX) has been making steady strides despite some recent fluctuations in its share. The company's stock has displayed significant resilience even amidst market surges, slightly contradicting the typical trend where a strong market generally boosts the values of top-performing stocks. Vertex registered growth in its shares, which was facilitated by Banque Pictet & Cie SA and Aberdeen Group plc's acquisition of Vertex shares. On a more negative note, inside sales were reported involving EVP's and Joy Liu. Vertex Pharmaceuticals aims for $12B in revenue by 2025 and has submitted applications for accelerated FDA approval. While the company's stock experienced several dips, Wells Fargo has increased Vertex's price target to $550. The company has promising therapeutics pipelines outside of Cystic Fibrosis treatments, including potential advancements in Nephrology. Vertex's renal pipeline was recognized as a major growth driver by Barclays. Vertex also posted a 9.5% decline over a six-day streak, attributed to multiple factors including the volatility of the biotech market. However, the stock recovery indicates a still potent investment opportunity.
